Etavopivat delivers Phase 3 success in sickle cell disease, satralizumab becomes the first positive Phase 3 result in MOGAD, AstraZeneca completes its triple-positive COPD biologic programme, and a busy week for paediatric medicine brings new approvals and data in type 1 diabetes, type 2 diabetes, and congenital adrenal hyperplasia.
A week spanning rare blood disorders, neurological autoimmune disease, chronic lung disease, oncology, endocrinology, and paediatric medicine delivered one of the most therapeutically diverse clusters of readouts so far in 2026. The sickle cell results from Novo Nordisk and the MOGAD data from Roche each represent potential first-in-class or first-ever approvals in their respective indications, while AstraZeneca’s completion of its COPD biologic programme establishes a foundation for what could become one of the most significant new respiratory therapies in years. Here, Life Science Daily News brings you the most significant clinical trial results 1 May 2026.
Novo Nordisk’s Etavopivat Meets Both Co-Primary Endpoints in Pivotal Phase 3 HIBISCUS Trial for Sickle Cell Disease
Novo Nordisk announced topline results from HIBISCUS, a pivotal Phase 3 trial evaluating once-daily oral etavopivat 400 mg in 385 adults and adolescents aged 12 years or older with sickle cell disease (SCD). The trial was a randomised, double-blinded, 52-week efficacy and safety study comparing etavopivat against placebo on top of standard of care. Etavopivat met both co-primary endpoints, demonstrating superior reduction in vaso-occlusive crises (VOCs) and superior improvement in haemoglobin response compared to placebo.
Patients treated with etavopivat showed a 27% reduction in the annualised rate of VOCs compared to placebo, and the median time to first VOC was substantially prolonged — 38.4 weeks in the etavopivat arm versus 20.9 weeks with placebo, a near-doubling of the VOC-free period. On the haemoglobin co-primary endpoint, 48.7% of patients in the etavopivat group achieved an increase in haemoglobin of greater than 1 g/dL at week 24, compared with just 7.2% in the placebo group, corresponding to an adjusted rate difference of 41.2%. As an exploratory analysis, etavopivat also significantly reduced the risk of blood transfusion. The safety profile was in line with previous etavopivat studies, and the drug appeared to be well tolerated.
Etavopivat is a once-daily orally available small molecule allosteric activator of red blood cell pyruvate kinase isozyme (PKR). In sickle cell disease, PKR activation reduces 2,3-diphosphoglycerate (2,3-DPG) levels and increases adenosine triphosphate (ATP) production. The reduction in 2,3-DPG improves haemoglobin-oxygen affinity, averting sickle haemoglobin polymerisation, while increased ATP production helps preserve red blood cell membrane integrity and deformability. Sickle cell disease affects approximately 8 million people worldwide and reduces lifespan by approximately 30 years compared to the general population. Etavopivat holds Fast Track, Rare Pediatric Disease, and Orphan Drug designations from the FDA, as well as Orphan Drug designation from the European Commission. Novo Nordisk plans to submit for the first regulatory approval of etavopivat in the second half of 2026, with full trial data to be presented at an upcoming scientific conference.
Roche’s Enspryng (Satralizumab) Reduces MOGAD Relapse Risk by 68% in First-Ever Positive Phase 3 Trial
Roche announced new data from the Phase 3 METEOROID study demonstrating that Enspryng (satralizumab) reduced the risk of a new relapse by 68% compared to placebo in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), meeting its primary endpoint (p=0.0025). The results were presented as a late-breaking oral presentation in the Clinical Trials Plenary Session at the 2026 American Academy of Neurology Annual Meeting in Chicago. METEOROID is the first randomised, controlled Phase 3 trial to demonstrate a positive result in this indication, and currently there are no approved therapies for MOGAD.
The primary endpoint measured time from randomisation to first MOGAD relapse during the double-blind treatment period. At 48 weeks, 87% of patients on Enspryng remained relapse-free compared with 67% on placebo, with onset of response observed as early as eight weeks. On key secondary endpoints, Enspryng reduced the annualised relapse rate by 66% (p=0.0030), cut the annualised rate of active MRI lesions across the optic nerves, brain, and spinal cord by 79% (p=0.0026), and reduced the proportion of patients requiring rescue therapy — steroids, plasma exchange, or intravenous immunoglobulins — by 73% (p=0.0024). A numerical 17% reduction in annualised hospitalisation rate was also observed, though this did not reach statistical significance (p=0.7528). No new safety signals were identified; the safety profile was consistent with Enspryng’s established data from more than a decade of clinical trial and post-approval experience in aquaporin-4 seropositive neuromyelitis optica spectrum disorder (NMOSD).
MOGAD is a rare autoimmune disease of the central nervous system characterised by unpredictable attacks of the optic nerves, spinal cord, or brain that can cause severe disability, vision loss, and accumulating neurological damage. METEOROID enrolled 188 adolescents and adults aged 12 years and older with MOGAD and at least one relapse in the prior 12 months or two attacks in 24 months. Participants were randomised 1:1 to receive satralizumab (dosed at 60 mg, 120 mg, or 180 mg based on body weight) or placebo subcutaneously, administered at weeks 0, 2, and 4, then every four weeks thereafter. Enspryng is a recycling antibody designed for sustained IL-6 receptor inhibition. Roche plans to submit data to regulatory authorities globally, including the FDA, EMA, and Japan, with peak sales for the MOGAD indication estimated at approximately 500 million Swiss francs.
AstraZeneca’s Tozorakimab Completes Triple-Positive Phase 3 COPD Programme with MIRANDA Trial Success
AstraZeneca announced positive high-level results from the pivotal Phase 3 MIRANDA trial, confirming that tozorakimab, a potential first-in-class IL-33 monoclonal antibody, met its primary endpoint of a statistically significant and clinically meaningful reduction in the annualised rate of moderate-to-severe COPD exacerbations. This result marks the third consecutive positive pivotal Phase 3 trial within AstraZeneca’s LUNA programme, following positive readouts from the OBERON and TITANIA trials announced in March 2026.
In MIRANDA, patients received tozorakimab 300 mg or placebo once every two weeks on top of standard of care inhaled therapy. The trial enrolled patients with COPD still experiencing moderate-to-severe exacerbations while on inhaled standard of care. The statistically significant exacerbation reduction was demonstrated in the primary population of former smokers and in the overall population, which included former and current smokers, and patients across all blood eosinophil counts and all stages of lung function severity. This all-comers efficacy profile is a meaningful commercial differentiator, as current biologics approved in COPD — including dupilumab — are primarily indicated for patients with elevated eosinophil counts, requiring biomarker testing to guide prescribing. No specific exacerbation reduction figures have been disclosed with the high-level results; full data will be presented at an upcoming medical meeting.
Tozorakimab is a potent human immunoglobulin monoclonal antibody targeting interleukin-33 (IL-33). It works by inhibiting IL-33 signalling in two ways, suppressing inflammation and disrupting the cycle of mucus dysfunction that are considered key disease drivers in COPD. COPD is the world’s third leading cause of death. The completion of the three-trial LUNA programme establishes a broad, consistent efficacy dataset across patient phenotypes and positions AstraZeneca to move towards regulatory submissions. The company has guided peak sales of $3–5 billion for the COPD indication, and has indicated it is also exploring expansion into bronchiectasis and asthma. Tozorakimab holds FDA Fast Track designation for both COPD and severe viral lower respiratory tract disease.
Merck and Eisai’s Welireg Triplet Fails Both Dual Primary Endpoints in Phase 3 LITESPARK-012 First-Line Kidney Cancer Trial
Merck and Eisai announced that the Phase 3 LITESPARK-012 trial failed to meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). The trial evaluated a triplet regimen comprising Merck’s HIF-2α inhibitor Welireg (belzutifan), its PD-1 blockbuster Keytruda (pembrolizumab), and Eisai’s tyrosine kinase inhibitor Lenvima (lenvatinib) as a first-line treatment for patients with clear cell renal cell carcinoma (ccRCC). The control arm received Keytruda plus Lenvima, the current approved standard of care combination. The trial enrolled 1,688 patients with histologically confirmed, treatment-naive, advanced ccRCC.
An interim analysis showed that neither the Welireg triplet nor a separately evaluated combination of Lenvima with MK-1308A — a co-formulation of Keytruda and Merck’s experimental antibody quavonlimab — generated superior results compared to the Keytruda-Lenvima doublet. Specific survival data were not disclosed in the companies’ news release; full results will be presented at a future medical congress. Merck and Eisai stated that the findings from LITESPARK-012 do not affect other ongoing trials within the broader LITESPARK clinical programme.
The failure is a significant setback for Merck, which had hoped to establish Welireg as a first-line backbone in ccRCC following two earlier positive Phase 3 readouts in the second-line (LITESPARK-011) and adjuvant (LITESPARK-022) settings. Welireg is the first approved HIF-2α inhibitor, a novel mechanism targeting tumour hypoxia signalling. Clear cell RCC accounts for approximately 80% of all kidney cancer cases. The result comes at a strategically sensitive time for Merck as it navigates the forthcoming patent expiration of Keytruda and looks to deepen its oncology pipeline. Analysts noted the miss could create an opening for competing HIF-2α programmes, including casdatifan from Arcus Biosciences.
FDA Expands Sanofi’s Tzield Approval to Children as Young as One Year Old in Stage 2 Type 1 Diabetes
Sanofi announced that the FDA has approved the supplemental biologic license application for Tzield (teplizumab-mzwv), expanding its indication from patients aged eight years and older to children as young as one year of age to delay the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. The approval was granted under a priority review process and is supported by one-year data from the PETITE-T1D Phase 4 study (NCT05757713), evaluating the safety and pharmacokinetics of Tzield in young children.
Tzield is a CD3-directed monoclonal antibody and the first and only disease-modifying therapy approved for autoimmune T1D. It was first cleared in the United States in November 2022 for adults and children aged eight years and older with stage 2 T1D. Stage 2 T1D is defined by the presence of two or more diabetes-related autoantibodies alongside dysglycaemia, prior to the onset of clinical insulin dependence. By targeting the autoimmune process driving beta-cell destruction before clinical symptoms develop, Tzield delays the progression to stage 3 — the insulin-dependent phase of the disease. The disease process often begins in very early childhood, and young children are frequently at highest risk of rapid progression. The expanded age indication allows intervention during a developmentally critical period when insulin management is particularly burdensome for caregivers.
Sanofi is also under FDA review for a further label expansion seeking approval to delay progression of stage 3 T1D in recently diagnosed patients aged eight years and older, potentially broadening Tzield’s use across the T1D disease continuum. Tzield is already approved in the European Union (as Teizeild), the UK, China, Canada, Israel, Saudi Arabia, the UAE, Kuwait, and Brazil for the stage 2 indication in adults and children aged eight years and older.
Novo Nordisk’s Oral Semaglutide Meets Primary Endpoint in PIONEER TEENS, the First Oral GLP-1 RA Trial in Paediatric Type 2 Diabetes
Novo Nordisk announced positive topline results from PIONEER TEENS (NCT04596631), a 52-week, randomised, double-blind, placebo-controlled Phase 3a trial evaluating oral semaglutide in 132 children and adolescents aged 10–17 years with type 2 diabetes. This is the first clinical trial of an oral GLP-1 receptor agonist (GLP-1 RA) therapy in a paediatric population. The trial met its primary endpoint of change from baseline in HbA1c at week 26, demonstrating a statistically significant and superior reduction in blood sugar of 0.83 percentage points compared to placebo.
Participants received oral semaglutide at maximum tolerated doses of 3 mg, 7 mg, or 14 mg once daily, on top of background treatment with metformin, basal insulin, or both. The safety and tolerability profile was consistent with the established semaglutide profile seen across the adult programme. The result is clinically significant in a population with substantial unmet need: type 2 diabetes in children and adolescents is a severe and progressive condition, and current guideline-recommended treatments of metformin and insulin are associated with high failure rates and adverse effects including hypoglycaemia and weight gain, respectively. In 2021, an estimated 14.6 million adolescents were living with type 2 diabetes globally, a figure projected to reach 20.9 million by 2030.
Oral semaglutide is currently marketed as Rybelsus in the EU and United States and is launching in the United States as the Ozempic pill in the second quarter of 2026. Novo Nordisk plans to file for regulatory approval of a paediatric label expansion for both brands in the United States and EU in the second half of 2026. If approved, oral semaglutide would become the first oral GLP-1 RA indicated for the treatment of type 2 diabetes in children and adolescents.
Neurocrine Biosciences’ Crenessity (Crinecerfont) Demonstrates Durable Glucocorticoid Dose Reductions at Two Years in Congenital Adrenal Hyperplasia
Neurocrine Biosciences announced the first presentation of two-year data from the Phase 3 CAHtalyst Adult study of Crenessity (crinecerfont) in adults with classic congenital adrenal hyperplasia (CAH), presented at the American Association of Clinical Endocrinology 2026 Annual Meeting in Las Vegas. The data demonstrated sustained, substantial reductions in glucocorticoid (GC) doses over two years, building upon the previously reported one-year results.
Approximately 70% of adult patients treated with Crenessity achieved and sustained physiologic-range glucocorticoid dosing at two years while maintaining androgen control. Among patients who were originally taking dexamethasone — a potent synthetic glucocorticoid with a significant side-effect burden — 75% were able to transition off this treatment, enabling a shift to more physiologic glucocorticoid regimens. These findings extend the evidence base for crinecerfont as a durable, non-glucocorticoid approach to controlling the adrenal androgen and ACTH excess that characterises classic CAH.
Classic congenital adrenal hyperplasia is a rare genetic condition caused by enzyme deficiency that impairs cortisol and aldosterone production, leading to compensatory overproduction of adrenal androgens. For decades, management has relied on supraphysiologic glucocorticoid doses to suppress androgen excess, but chronic exposure to high GC doses is associated with significant long-term cardiometabolic comorbidities, reduced bone density, mental health impacts, and other cumulative risks. Crenessity is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist that reduces ACTH and adrenal androgen levels through a non-glucocorticoid mechanism, enabling lower, more physiologic GC dosing. The two-year durability data represent the most extended clinical evidence yet from the largest interventional trial conducted in classic CAH. Neurocrine plans to present additional two-year data across clinical endpoints at upcoming medical meetings.
Monopar Therapeutics’ ALXN1840 Delivers Superior Neurological Outcomes Over Standard of Care in Phase 3 Wilson Disease Trial
Monopar Therapeutics announced new analyses from the randomised controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) in Wilson disease, presented at the American Academy of Neurology Annual Meeting 2026 in Chicago. In the subgroup of patients with neurological symptoms at baseline — the population with the most significant unmet need — ALXN1840 demonstrated substantially greater neurological benefit and significantly less worsening than standard of care through week 48.
In patients with neurological symptoms at baseline, only 9% of those receiving ALXN1840 experienced worsening compared with 25% receiving standard of care. Conversely, 45% of patients on ALXN1840 showed improvement, compared with 32% on standard of care. These differences were maintained at week 96, indicating durability of effect beyond the initial 48-week period. Across the broader Phase 3 FoCus trial, ALXN1840 demonstrated rapid and sustained copper mobilisation — its primary endpoint — and durable clinical improvement over 645 patient-years of follow-up in 266 patients, with a favourable safety and tolerability profile.
Wilson disease is a rare autosomal recessive disorder of copper metabolism in which defective ATP7B protein function leads to accumulation of toxic copper in the liver, brain, and other organs, causing progressive hepatic, neurological, and psychiatric damage. Current standard of care consists of copper chelators and zinc salts that have been in clinical use for decades, with limited evidence of neurological efficacy and tolerability concerns. ALXN1840 is a first-in-class Albumin Tripartite Complex (ATC) activator that rapidly mobilises excess copper and sequesters it tightly, suppressing its redox reactivity, limiting oxidative damage, and blocking transport across the blood-brain barrier. Monopar plans to submit a New Drug Application to the FDA in mid-2026 on the basis of these results, supported by the full FoCus trial dataset.
Looking Ahead
This week’s clinical trial results 1 May 2026 span an exceptional breadth of disease areas and therapeutic modalities, reflecting a pipeline operating at considerable pace across rare disease, oncology, endocrinology, and immunology. Etavopivat’s Phase 3 success adds a credible oral, disease-modifying option to sickle cell disease for the first time in years — and at a fraction of the cost profile of approved gene therapies — while Roche’s MOGAD data end a long era of off-label management for a condition with no approved treatment. AstraZeneca’s completion of the LUNA COPD programme with three positive Phase 3 trials represents one of the most comprehensive evidence packages assembled for a biologic in chronic respiratory disease. In contrast, the LITESPARK-012 failure is a timely reminder that even well-validated mechanisms and established drug combinations cannot guarantee first-line success in heavily competed oncology indications. The paediatric results – Tzield in young children with stage 2 T1D, oral semaglutide in adolescents with type 2 diabetes, and two-year Crenessity durability data in CAH – collectively underscore how rapidly precision medicine is extending into younger patient populations previously reliant on blunt pharmacological tools. And Monopar’s ALXN1840 data in Wilson disease represent a compelling case for a genuinely new mechanism in a rare neurological disorder that has lacked innovation for decades. Life Science Daily News will continue to bring you accurate, timely coverage of the clinical trial results 1 May 2026 that matter most across the global life sciences pipeline.
